Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15374789 | 1.00 | MEN1 (0.61) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL15481360 | 0.92 | MEN1 (0.53) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL15481362 | 0.92 | MEN1 (0.56) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL15481361 | 0.92 | MEN1 (0.53) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL15259238 | 0.88 | MEN1 (0.62) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL15929806 | 0.88 | MEN1 (0.56) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL2828107 | 0.88 | MEN1 (0.62) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL12872270 | 0.88 | MEN1 (0.62) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL8522763 | 0.88 | MEN1 (0.62) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL15983809 | 0.87 | MEN1 (0.53) | MEN1LMNACYP3A4KMT2ANEU1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9250238-B2 | Pathogen detection | PURDUE RESEARCH FOUNDATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-9181281-B2 | Prodrugs of neuraminidase inhibitors | SineVir Therapeutics LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-9150498-B2 | Process for the preparation of oseltamivir and methyl 3-epi-shikimate | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-10-06 | — | — | US | disclosed |
| US-9139514-B2 | Process for producing oseltamivir phosphate and intermediate compound | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-9132126-B2 | Phenyl-isoxazole derivatives and preparation process thereof | IL-YANG PHARM. CO., LTD. (KR) | 2015-09-15 | — | — | US | disclosed |
| US-9040738-B2 | Intermediate compounds of tamiflu, methods of preparation and uses thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-26 | — | — | US | disclosed |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140243537-A1 | PROCESS FOR THE PREPARATION OF OSELTAMIVIR AND METHYL 3-EPI-SHIKIMATE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-28 | — | — | US | disclosed |
| US-20140221662-A1 | INTERMEDIATE COMPOUNDS OF TAMIFLU, METHODS OF PREPARATION AND USES THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2014-08-07 | — | — | US | disclosed |
| US-20140155350-A1 | Prodrugs of Neuraminidase Inhibitors | SineVir Therapeutics LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140051756-A1 | METHOD FOR PREVENTING OR TREATING ARRHYTHMIA, METHOD FOR PREVENTING OR TREATING ATRIAL FIBRILLATION, MODEL OF SUSTAINED ATRIAL FIBRILLATION, METHOD FOR PRODUCING THE MODEL, AND METHOD FOR SCREENING FOR ATRIAL FIBRILLATION INHIBITOR | TOHO UNIVERSITY (JP) | 2014-02-20 | — | — | US | disclosed |
| US-20140031364-A1 | PHENYL-ISOXAZOL DERIVATIVES AND PREPARATION PROCESS THEREOF | IL-YANG PHARM. CO., LTD. (KR) | 2014-01-30 | — | — | US | disclosed |
| US-20130296600-A1 | PROCESS FOR PRODUCING OSELTAMIVIR PHOSPHATE AND INTERMEDIATE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8501980-B2 | Process for producing oseltamivir phosphate and intermediate compound | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20130196872-A1 | PATHOGEN DETECTION | PURDUE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120058937-A9 | Prodrugs of Neuraminidase Inhibitors | TSRL, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110160127-A1 | Prodrugs of Neuraminidase Inhibitors | TSRL, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110082302-A1 | Process for Producing Oseltamivir Phosphate and Intermediate Compound | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243537-A1 | PROCESS FOR THE PREPARATION OF OSELTAMIVIR AND METHYL 3-EPI-SHIKIMATE | CYP51A1, CYP2B6, CYP2C8 | MEN1 4095/4885LMNA 4533/4885CYP3A4 14/4885 |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | MEN1 4824/4885LMNA 3149/4885CYP3A4 2263/4885 |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | MEN1 4824/4885LMNA 3149/4885CYP3A4 2263/4885 |
| US-20140051756-A1 | METHOD FOR PREVENTING OR TREATING ARRHYTHMIA, METHOD FOR PREVENTING OR TREATING ATRIAL FIBRILLATION, MODEL OF SUSTAINED ATRIAL FIBRILLATION, METHOD FOR PRODUCING THE MODEL, AND METHOD FOR SCREENING FOR ATRIAL FIBRILLATION INHIBITOR | UGGT1, GUSB, KCNH1 | MEN1 3864/4885LMNA 1043/4885CYP3A4 192/4885 |
| US-20110160127-A1 | Prodrugs of Neuraminidase Inhibitors | NEU1, ANPEP, NEU4 | MEN1 3525/4885LMNA 1938/4885CYP3A4 416/4885 |
| US-20120058937-A9 | Prodrugs of Neuraminidase Inhibitors | NEU1, ANPEP, NEU4 | MEN1 3525/4885LMNA 1938/4885CYP3A4 416/4885 |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | MEN1 4824/4885LMNA 3149/4885CYP3A4 2263/4885 |
| US-20140155350-A1 | Prodrugs of Neuraminidase Inhibitors | NEU1, ANPEP, NEU4 | MEN1 3525/4885LMNA 1938/4885CYP3A4 416/4885 |
| US-20140031364-A1 | PHENYL-ISOXAZOL DERIVATIVES AND PREPARATION PROCESS THEREOF | PIR, ALPL, PIGS | MEN1 4678/4885LMNA 1031/4885CYP3A4 6/4885 |
| US-20110082302-A1 | Process for Producing Oseltamivir Phosphate and Intermediate Compound | CYP2B6, CYP2D6, UMPS | MEN1 1634/4885LMNA 4441/4885CYP3A4 6/4885 |
| US-20130296600-A1 | PROCESS FOR PRODUCING OSELTAMIVIR PHOSPHATE AND INTERMEDIATE COMPOUND | CYP2B6, CYP2D6, UMPS | MEN1 1634/4885LMNA 4441/4885CYP3A4 6/4885 |
| US-20140221662-A1 | INTERMEDIATE COMPOUNDS OF TAMIFLU, METHODS OF PREPARATION AND USES THEREOF | NNMT, FLT3, TPMT | MEN1 2258/4885LMNA 1845/4885CYP3A4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.